Sign in

Lost your password?
(close)

Vectura Group plc

Last updated: 13.02.2014

Address: One Prospect West, Chippenham, Wiltshire, SN14 6FH,United Kingdom

Tel: +44 (0)1249 667700

Web: http://www.vectura.com/

Company description

Vectura Group plc develops inhaled therapies principally for the treatment of respiratory diseases. Vectura’s main products target diseases such as asthma and chronic obstructive pulmonary disease (COPD), a growing market that is currently estimated to be worth in excess of $25 billion.

Vectura seeks to develop certain programmes itself where this will optimise value. Vectura’s formulation and inhalation technologies are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura’s business strategy.

For further information, please visit Vectura’s website at www.vectura.com

Products and services

Vectura has six products marketed by its partners and a portfolio of drugs in clinical and pre-clinical development, a number of which have been licensed to major pharmaceutical companies. Vectura has development collaborations and licence agreements with several pharmaceutical companies, including Novartis, Sandoz (the generics arm of Novartis), Baxter and GlaxoSmithKline (GSK).

Related

We use cookies to ensure that we give you the best experience on our site. For more info click here